PATENT CLAIM ANALYSIS

Application Number: 16269339
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-06
Patent Classification: ["514", "303000"]

Abstract:
Methods and compositions are provided for the treatment of familial exudative vitreoretinopathy (FEVR) through the administration of a therapeutically effective amount of a sphingosine-1-phosphate receptor type 2 (S1PR2) antagonist. Also provided herein are (Z)-3-((2,6-dichloropyridin-4-yl)amino)-3-(((4-isopropyl-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)methyl)amino)acrylonitrile and analogs thereof, and their use in treating retinopathies and diseases characterized by insufficient angiogenesis.

Claim (Index 17):
The method of  claim 16 , wherein the retinopathy is selected from the group consisting of diabetic retinopathy, macular degeneration, hypertensive retinopathy, radiation retinopathy, solar retinopathy, retinopathy of prematurity (ROP), Norrie disease (ND), familial exudative vitreoretinopathy (FEVR), Coats' disease, sickle cell retinopathy, and retinitis pigmentosa.

Metadata:
- Claim Count in Document: 25.0
- Percentile: 99.0
- Lexical Diversity: 1.48148
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15316072', '13929451', '14436145', '10540371', '11890199']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8358853011525733
- 35 USC 102 Novelty (BERT): 0.5367380675922685
- Combined Prediction Score: 0.8059705777965428
- Mean Citation Score: 313.490862
- Max Citation Score: 390.1501
- Similarity Product: 224.84827960380912

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test